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Anthracycline-based chemotherapy remains standard treatment for peripheral T-cell lymphoma (PTCL) although its beneﬁts
have been questioned. We performed systematic literature review and meta-analyses examining the complete response (CR) and
overall survival (OS) rates for patients with PTCL. The CR rate for PTCL patients ranged from 35.9% (95% CI 23.4–50.7%) for
enteropathy-type T-cell lymphoma (ETTL) to 65.8% (95% CI 54.0–75.9%) for anaplastic large cell lymphoma (ALCL). The 5-year
OS was 38.5% (95% CI 35.5–41.6%) for all PTCL patients and ranged from 20.3% (95% CI 12.5–31.2%) for ETTL to 56.5%
(95% CI 42.8–69.2%) for ALCL. These data suggest that there is marked heterogeneity across PTCL subtypes in the beneﬁts of
anthracycline-based chemotherapy. While anthracyclines produce CR in half of PTCL patients, this yields reasonable 5-year OS
for patients with ALCL but not for those with PTCL-NOS or ETTL. Novel agents and regimens are needed to improve outcomes
for these patients.
1.Introduction
Peripheral T-cell lymphoma (PTCL) is a heterogeneous gro-
up of non-Hodgkin’s lymphomas (NHL) characterized by
poor treatment outcome with conventional chemotherapy.
Anthracycline-based chemotherapy remains the standard
treatment for patients with PTCL although such regimens
have failed to induce sustained remissions for most patients.
The role of anthracyclines in the treatment of PTCL remains
debatable. The International PTCL Clinical and Pathologic
Review Project retrospectively demonstrated no diﬀerence
in overall survival (OS) comparing patients who did or did
not receive an anthracycline for PTCL [1]. Prior studies have
established worse outcome for PTCL compared to aggressive
B-cell NHL treated with anthracycline-based chemotherapy,
in terms of response, relapse, and OS rates [2–4]. Since there
are no large randomized prospective studies that compare
the beneﬁts of anthracycline-based therapies to other strate-
gies, we conducted a systematic literature review and meta-
analysis of ﬁrst-line therapy for PTCL patients to elucidate
theroleofanthracyclinesandexaminethecompleteresponse
(CR) and OS rates associated with anthracycline-based regi-
mens.
Given the well established favorable outcomes for patie-
nts with anaplastic lymphoma kinase (ALK) positive anap-
lastic large cell lymphomas (ALCL) [5], along with the
heterogeneity in response and survival rates across PTCL
subgroups, we focused our analyses on non-ALCL PTCL and
performedsubgroupmeta-analysesontheoutcomesofanth-
racycline-based regimens for patients with PTCL- not2 ISRN Hematology
otherwise speciﬁed (NOS), angioimmunoblastic T-cell lym-
phoma (AITL), natural-killer/T-cell (NK/T-cell) NHL, and
enteropathy-type T-cell lymphoma (ETTL) subtypes.
2. Methods
2.1. Systematic Literature Review. Studies were identiﬁed by
searching Medline and Google Scholar databases through
2010 and the conference proceedings of the American
Society of Hematology and the American Society of Clin-
ical Oncology for the years 2003 to 2010. Each search
used combinations of the terms “Peripheral T-Cell Lym-
phoma,” “T-Cell Lymphoma,” “Anthracyclines,” “CHOP,”
“Doxorubicin,” “Mitoxantrone,” “Daunorubicin,” “CVAD,”
and “Adriamycin.” Two reviewers (A. N. AbouYabis and P. J.
Shenoy) performed study selection, quality assessment, and
dataextractionindependentlyusingstandardizedforms.Any
disagreement was resolved by a third reviewer (C. R. Flowers
or M. J. Lechowicz).
2.2. Meta-Analysis Inclusion Criteria, Study Selection, and
Data Extraction. Criteria for including studies in the meta-
analysis were (1) studies involving patients with untreated
PTCL (studies involving relapsed/refractory PTCL patients
were included only if they provided separate outcome
data for untreated PTCL patients), (2) treatment with
anthracycline-based regimen, (3) reporting in English, and
(4) reporting of CR rates and/or 5-year OS. Only full text
r e p o r t sw e r ei n c l u d e da sm o s ta b s t r a c t sp r e s e n t e dp r e l i m -
inary results with a short followup. The primary outcome
measures were OS and CR. Extracted data also included type
ofstudy(prospective/retrospective),PTCLsubtype,pretreat-
mentdiseasestatus,andmedianfollow-uptime.Studieswere
carefully screened for possible duplication of study popula-
tion based on the participating institutions and period of
presentation of patients. Additional studies not included in
the meta-analysis were discussed in the narrative review.
2.3. Data Analysis and Statistical Methods. Studies included
in the subtype-speciﬁc and combined PTCL meta-analyses
were evaluated for heterogeneity as described below and
evaluated for suitability for pooling. Pooled estimates of
the CR rate and the 5-year OS for patients treated with
anthracycline-containing regimens were computed. DerSi-
monian and Laird random eﬀects [6] and Mantel-Haenszel
ﬁxed eﬀect models [7] were used to combine subgroups
to determine the overall eﬀects. For each analysis, a forest
plot was generated to display results. The study-to-study
variance (tau-squared) was not assumed to be the same for
all subgroups; this value was computed within subgroups
and not pooled across subgroups. The consistency of results
(eﬀect sizes) among studies was investigated by means of two
heterogeneity tests, the χ2-based Cochran’s Q test, and the I2
statistic.Toevaluateheterogeneityacrossreportedresults,we
performedvisualinspectionofforestplotsandcomparedthe
ﬁxed eﬀects and random eﬀects models.
We considered that heterogeneity was present when the
P value of the Cochran’s Q test was <.1 and I2 statistic
was >50%. Potential publication bias was estimated with the
Begg and Mazumdar rank correlation test [8], Egger’s test of
intercept [9], and Duval and Tweedie’s trim and ﬁll test [10].
We also evaluated whether our estimates of CR and 5-year
OS were inﬂuenced by publication bias by assessing funnel
plots of the logit of the estimate versus its standard error and
by comparing pooled estimates of CR and 5-year OS rates
for full text reports and studies reported as abstracts only.
Tests for publication bias were repeated after inclusion and
exclusion of abstracts published during that timeframe but
notlaterpublishedasfullmanuscriptstodetermineifadding
abstracts in the meta-analyses changed the results and added
signiﬁcant value.
Univariate metaregression analyses were conducted to
identify patient characteristics (age > 60 years, male gender,
stage III/IV, B symptoms, extranodal disease, LDH >upper
limit of normal, ECOG performance status ≥ 2, bone mar-
row involvement, and high/high intermediate International
prognosticindexscore)thatweresigniﬁcantpredictorsofCR
rate and 5-year OS. A two-sided alpha error of 0.05 was used
to declare statistical signiﬁcance. Statistical analyses were
performed using SAS software, Version 9.1.3 (SAS Institute
Inc., Cary, NC, USA) and Comprehensive Meta Analysis,
Version 2 (Biostat Inc.).
3. Results
Overall, 389 potentially relevant references describing ini-
tial treatments for PTCL were identiﬁed and screened
for retrieval. Among these, 44 studies involved ﬁrst-line
therapy with anthracyclines; six studies were excluded due
to possible duplication of study population, and six studies
published as abstracts only were excluded. Figure 1 depicts
the exclusion of articles. Thirty-one studies (13 prospective
and 18 retrospective) that involved 2,815 patients and met
all the inclusion and exclusion criteria were included in the
meta-analyses (Tables 1 and 2).
3.1. Systematic Literature Review
3.1.1. Response to Anthracycline Regimens across PTCL Subty-
pes. The CR rates associated with anthracycline-based regi-
mensrangedfrom30%to76%acrossstudies[2,4,12,23,24,
27–29, 32, 38, 39]. As expected, ALK-positive ALCL showed
a higher CR rate with anthracycline-based chemotherapy
than other T-cell lymphomas [4, 40]. Within the non-
ALCL PTCL subgroups, treatment with cyclophosphamide-
doxorubicin-vincristine-prednisone (CHOP) or CHOP-like
chemotherapy produced CR in 36–70% of AITL patients,
in 44–64% of PTCL-NOS patients, and in 33% of ETTL
patients [24, 32, 36, 39].
NK/T-cell NHL demonstrated CR rates ranging between
40% and 70% in localized disease and a CR rate of 25%
in advanced disease [22, 26, 33]. In patients with stage I/II
disease, radiotherapy (RT) improved CR rates to 52–100%
[25, 30, 31, 35, 37, 41–44]. Given the high rate of disease
progression during standard CHOP chemotherapy (35%) as
well as the previously documented superiority of CHOP-
14 over standard CHOP by the German high-grade NHL
study group [45, 46], two cycles of dose-intense CHOP every
two weeks (DI-CHOP-14) followed by RT and consolidationISRN Hematology 3
reasons: non-English (n = 55); nonhuman
Potentially relevant papers identiﬁed and
screened for retrieval of clinical studies
(n = 389)
Papers excluded, due to the following
(n = 14); nonclinical trials (n = 227)
Abstracts retrieved for further evaluation
(n = 93)
Trials that did not involve anthracyclines
(n = 49)
Publications retrieved for more detailed
evaluation (n = 44)
Abstracts without complete manuscripts
(n = 6)
Studies included in meta-analysis (n = 31)
Studies excluded due to possible
duplication of study population (n = 7)
(n = 13) prospective ; retrospective (n = 18)
Figure1:Quorumﬂowchartofstudyinclusion.Illustrationofthenumberofarticlesidentiﬁedinliteraturesearchandreasonsforexclusion.
Thirty studies met the inclusion and exclusion criteria.
therapy with four cycles of standard CHOP thereafter was
investigated by Kim et al. and Lee et al. in patients with
localizednasalNK/T-cellNHL[18,47].Overall,thisregimen
improved the CR rate to 76%, as compared to the 58%
achieved by standard CHOP-21. The authors believed that
this approach also reduced locoregional failure, likely due to
early institution of RT [18, 47].
3.1.2. CHOP versus More Intensive Anthracycline-Based
Regimens. There have been conﬂicting data regarding the
beneﬁts of intensive anthracycline-based chemotherapy
regimens compared with CHOP in the ﬁrst-line treatment
of PTCL and other aggressive NHLs. A randomized phase
3 trial demonstrated no signiﬁcant diﬀerence in the partial
response, CR rates, or 3-year OS comparing CHOP and
three intensive chemotherapy regimens for all patients with
aggressive NHL [48]. The prospective “LTP95” protocol
showed no diﬀerence in event-free survival (EFS) or OS
between CHOP and vinblastine-ifosfamide-cisplatin and
doxorubicin-bleomycin-vinblastine-dacarbazine regimen
[49]. In a retrospective study comparing cohorts of PTCL
patients, excluding ALCL, the CR rates were similar between
CHOP and more intensive regimens, including hyper-CVAD
(58% versus 59%, P = .99), with an estimated 3-year OS
rates of 43% and 49%, respectively [34]. There has, however,
been one randomized trial showing an 18% diﬀerence in
disease-free survival (DFS) at 5 years (P = .0002) favoring
intensive chemotherapy over CHOP [50].
3.1.3. Relapse following Anthracycline Regimens. PTCL
patients treated with anthracycline-based regimens generally
relapse at a higher rate than patients with B-NHL (43%
versus 29%, P<. 001) and have a signiﬁcantly shorter
freedom-from-relapse survival (median: 34 months versus
not reached for B-cell; P = .002) [4]. Moreover, disease
progression during chemotherapy occurred in 30%–40% of
patients [26, 32, 47, 51]. Relapse rates for PTCL varied by
subtype [24, 36]. A study by the British Columbia Cancer
Agency showed more favorable 5-year progression-free
survival (PFS) for ALCL and PTCL-NOS subtypes (28%)
followed by ETTL (22%), NK/T-cell, and AITL subtypes
(13–15%) [32].
3.1.4. Diﬀerences in Survival across PTCL Subtypes. Five-year
OS ranged between 63% and 75% for ALCL versus 26%–
36% for non-ALCL subtypes [4, 24, 29, 40, 52]. Among
non-ALCL PTCL subtypes, the 5-year OS ranged between
28% and 36% in AITL, 45% in PTCL-NOS, and <25% in
patients with ETTL [24, 32, 36]. For NK/T-cell NHL, 5-
yearOSwas25%–77%dependingonthetreatmentmodality
[26, 31–33, 35, 43]. Chemotherapy plus RT resulted in the
same 5-year OS as RT, and both modalities were superior to
chemotherapy alone [26, 31, 33, 35, 37, 43].
3.2. Meta-Analyses
3.2.1. Complete Remission Rates. In order to determine if
pooling the studies for subtype-speciﬁc meta-analysis and as4 ISRN Hematology
Table 1: Prospective studies included in meta-analyses.
Study, Year Regimen PTCL subgroup∗ n CR% OS
Coiﬀer et al., 1990 [3] ACVB (LNH84) PTCL-combined 108 72.0
Liang et al., 1992 [11]B A C O P ± Methotrexate PTCL-combined 42 67.0 3yr 52%
Siegert et al., 1992 [12]P r e d ± COPBLAM/IMVP AITL 39 33.0 3yr 41%
Karakas et al., 1996 [13] VACPE PTCL-combined 27 77.0 5yr 48%
Gisselbrecht et al., 1998 [4] Anthracycline-based PTCL-combined 288 54.0 5yr 41%
ALCL 60 72.0 5yr 64%
Non-ALCL PTCL 228 49.0 5yr 35%
Daum et al., 2003 [14] CHOP ETTL 23 35.0 2yr 49%
Reimer et al., 2004 [15] CHOP PTCL-combined 30 43.3
PTCL-NOS 12 41.7
AITL 12 33.3
ALK Neg ALCL 4 50.0
NK/T nasal 2 100.0
W¨ ohrer et al., 2004 [16] CHOEP ETTL 10 30.0
Kim et al., 2006 [17] CHOP-EG PTCL-combined 26 61.5 1yr 70%
PTCL-NOS 14 57.1
AITL 2 50.0
ALK Neg ALCL 2 100.0
NK/T nasal 8 62.5
Lee et al., 2006 [18] DI-CHOP + RT NK/T nasal 17 76.5 3yr 67%




Bishton and Haynes, 2007 [20] HDCT + PBSCT ETTL 6 83.3
Takamatsu et al., 2010 [21] THP-COP Non-ALCL PTCL 17 41.0 3yr 35%
PTCL: peripheral T-cell lymphoma; n: number of patients; CR: complete response; OS: overall survival; ACVB: doxorubicin, cyclophosphamide,
vindesine, bleomycin, and prednisone; BACOP: Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone; Pred, prednisolone; COPBLAM:
cyclophosphamide, vincristine, and prednisone with bleomycin, doxorubicin, and procarbazine; IMVP: ifosfamide, methotrexate, and etoposide; VACPE:
vincristine, doxorubicin, cyclophosphamide, prednisone, and etoposide; NK/T nasal, NK/T-cell lymphoma nasal type; NOS: not otherwise speciﬁed;
ALCL: anaplastic large cell lymphoma; AITL: angioimmunoblastic T-cell lymphoma; ETTL: enteropathy-type T-cell lymphoma; CHOP: cyclophosphamide,
doxorubicin, vincristine, and prednisone; RT: radiation therapy; CMT: combined modality treatment; V: vincristine; syst, systemic; Neg: negative; CHOEP:
cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone; CT: chemotherapy; CVAD: cyclophosphamide, doxorubicin, vincristine, and
dexamethasone; VIP: vinblastine, ifosfamide, and cisplatin; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; EG: etoposide and gemcitabine; DI:
dose-intensive; CEOP-B: cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin; HDCT: high-dose chemotherapy; PBSCT: peripheral blood
stem cell transplant; THP-COP: pirarubicin, cyclophosphamide, vincristine, and prednisone.
∗PTCL-combinedrepresentsthewholegroupofPTCLpatients.IncaseswherestudiesseparatedALK-positiveandALK-negativeALCLandprovidedseparate
results for the two subgroups, ALK-positive patients were excluded from the meta-analysis. Non-ALCL PTCL indicates PTCL without any ALCL subtype
included.
an entire PTCL group was appropriate, we ﬁrst determined
the P value for the Cochran’s Q test and the I2 statistic for
the studies to identify and quantify the level of heterogeneity
[53, 54].
When combining studies to estimate CR, the P value for
the Cochran’s Q test was <.01 and the I2 statistic was 59%
indicating substantial heterogeneity [53]; hence, a pooled
estimate of the CR rate for all PTCL patients was not
calculated. In the subtype-speciﬁc analysis, AITL, ALCL, and
NK/T nasal demonstrated no evidence of heterogeneity (all
I2 < 50%) and hence were pooled for subtype-speciﬁc meta-
analysis.
Analyses by PTCL subtype (Figure 2, black diamonds)
revealed the following CR rates: ALCL 65.8% (95% CI 54.0–
75.9%), NK/T 57.8% (95% CI 50.4–64.9%), AITL 42.1%
(95% CI 33.9–50.9%), and ETTL 35.9% (95% CI 23.4–
50.7%). ForNK/T celllymphoma,theCR ratesfortreatment
with chemotherapy alone and combination chemoradiationISRN Hematology 5
Table 2: Retrospective studies included in meta-analyses.
Study, Year Regimen PTCL subgroup∗ n CR% OS
Kwong et al., 1997 [22] Anthracycline-based NK/T nasal 24 66.7
Cheung et al., 1998 [2] Anthracycline-based PTCL-NOS 24 69.6 2yr 63%
NK/T nasal 51 56.0 2yr 43%
L¨ opez-Guillermo et al., 1998 [23] Anthracycline-based PTCL-combined 174 49.0 4yr 38%
PTCL-NOS 95 47.0 4yr 32%
ALCL 30 69.0
AITL 22 37.0
NK/T nasal 14 46.0
ETTL 12 27.0
Pautier et al, 1999 [24] CHOP-like AITL 33 60.6 5yr 36%
Ribrag et al., 2001 [25]C H O P - t y p e ± RT NK/T nasal 7 28.6
Cheung et al., 2002 [26] CMT NK/T nasal 61 65.6 5yr 41%




NK/T nasal 25 52.0




R¨ udiger et al., 2002 [29] Adriamycin-based Non-ALCL PTCL 96 5yr 26%
Chim et al., 2004 [30] Anthracycline-based + RT NK/T nasal 47 65.9
Li et al., 2004 [31] CHOP-based NK/T nasal local 18 50.0 5yr 15%
CHOP-based + RT NK/T nasal local 27 74.1 5yr 59%
CHOP-based NK/T nasal syst 10 60.0 5yr 30%
CHOP-based + RT NK/T nasal syst 10 30.0 5yr 20%
Savage et al., 2004 [32] CHOP-type PTCL-NOS 117 64.1 5yr 35%
ALCL 33 55.0 5yr 43%
AITL 10 70.0 5yr 36%
NK/T nasal 17 73.0 5yr 24%
ETTL 9 33.0 5yr 22%
You et al., 2004 [33] CT + RT NK/T nasal 16 5yr 42%
CT NK/T nasal 15 5yr 20%
Escal´ on et al., 2005 [34] CHOP Non-ALCL PTCL 24 58.0 3yr 43%
CHOP Intensive Non-ALCL PTCL 52 59.0 3yr 49%
Kim et al., 2005 [35] CHOP/COPBLAM-V + RT NK/T nasal 16 37.5 5yr 59%
RT NK/T nasal 33 52.0 5yr 76%
Sonnen et al., 2005 [36] CHOP-type PTCL-combined 125 53.0 5yr 43%
ALCL 21 71.0 5yr 61%
PTCL-NOS 70 55.0 5yr 45%
AITL 34 36.0 5yr 28%
Li et al., 2006 [37] CHOP-based + RT NK/T nasal 71 84.5 5yr 76%
CHOP-type alone NK/T nasal 3 33.36 ISRN Hematology
Table 2: Continued.
Study, Year Regimen PTCL subgroup∗ n CR% OS
Vose et al., 2008 [1] Anthracycline-based PTCL-NOS 340 5yr 32%
ALK Neg ALCL 72 5yr 49%
AITL 243 5yr 32%
NK/T nasal 136 5yr 42%
ETTL 62 3yr 20%
PTCL: peripheral T-cell lymphoma; n: number of patients; CR: complete response; OS: overall survival; ACVB: doxorubicin, cyclophosphamide,
vindesine, bleomycin, and prednisone; BACOP: Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone; Pred, prednisolone; COPBLAM:
cyclophosphamide, vincristine, and prednisone with bleomycin, doxorubicin, and procarbazine; IMVP: ifosfamide, methotrexate, and etoposide; VACPE:
vincristine, doxorubicin, cyclophosphamide, prednisone, and etoposide; NK/T nasal, NK/T-cell lymphoma nasal type; NOS: not otherwise speciﬁed;
ALCL: anaplastic large cell lymphoma; AITL: angioimmunoblastic T-cell lymphoma; ETTL: enteropathy-type T-cell lymphoma; CHOP: cyclophosphamide,
doxorubicin, vincristine, and prednisone; RT: radiation therapy; CMT: combined modality treatment; V: vincristine; syst, systemic; Neg: negative; CHOEP:
cyclophosphamide, doxorubicin, etoposide, vincristine, and prednisone; CT: chemotherapy; CVAD: cyclophosphamide, doxorubicin, vincristine, and
dexamethasone; VIP: vinblastine, ifosfamide, and cisplatin; ABVD: doxorubicin, bleomycin, vinblastine, and dacarbazine; EG: etoposide and gemcitabine; DI:
dose-intensive; CEOP-B: cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin; HDCT: high-dose chemotherapy; PBSCT: Peripheral blood
stem cell transplant.
∗PTCL-combinedrepresentsthewholegroupofPTCLpatients.IncaseswherestudiesseparatedALK-positiveandALK-negativeALCLandprovidedseparate
results for the two subgroups, ALK-positive patients were excluded from the meta-analysis. Non-ALCL PTCL indicates PTCL without any ALCL subtype
included.
therapy were 57.1% (95% CI 48.8–64.9%) and 68.3%
(95% CI 60.7–75.0%), respectively. To address the disparate
outcomes in ALK-positive ALCL, we performed a meta-
analysis of studies removing data for this PTCL subset.
With ALK-positive ALCL patients excluded, the estimated
CR rate for PTCL patients receiving anthracycline-based
chemotherapy(n = 1,191)was50.1%(95%CI44.9–55.3%).
T h ef u n n e lp l o t( Figure 3) of studies included in the
meta-analysis of CR rates appeared symmetrical. Begg and
Mazumdar’s rank correlation test (P = .16), Egger’s test of
intercept(P = .16),andDuvalandTweedie’strimandﬁlltest
(no studies added) all indicated that there was no clear evi-
dence of publication bias. Pooled CR estimates of abstracts
andfulltextreportswerenotsigniﬁcantlydiﬀerent(P = .49).
Tests for publication bias repeatedafterinclusion of abstracts
showed that adding abstracts did not add any signiﬁcant
informational value. The univariate metaregression analysis
ofprospectivestudiesrevealedthatageatdiagnosis>60(P =
.03), the presence of stage III/IV (P = .046), B-symptoms
(P = .012), and high/high-intermediate IPI (P = .056) were
signiﬁcant predictors of lower CR rates (Table 3).
3.2.2. Five-Year Survival Rates. Of the studies included in the
meta-analyses for 5-year OS, only two were prospective stud-
ies [4, 13]. The P value for the Cochran’s Q test was <.01 and
the I2 statistic was 78% indicating substantial heterogeneity
[53]; hence, a pooled estimate of 5-year OS for all PTCL
patients was not calculated. Among the subtypes, studies
reporting results for AITL, ALCL, and ETTL demonstrated
no evidence of heterogeneity (all I2 = 0%) and hence were
pooledforsubtype-speciﬁcmeta-analysis.Thepooled5-year
OS estimates for PTCL subtypes demonstrating no evidence
of heterogeneity were as follows: ALCL 56.5% (95% CI 42.8–
69.2%),AITL32.1%(95%CI27.2–37.5%),andETTL20.3%
(95% CI 12.5–31.2%) (Figure 4). When ALCL was excluded,
the 5-year OS for all PTCL patients (n = 1,691) was 36.6%
(95% CI 31.5–42.0%).
T h ef u n n e lp l o t( Figure 5) of studies included in the
meta-analysis of 5-year OS rates showed wide variance but
was predominantly symmetrical. The Begg and Mazumdar’s
rank correlation test (P = .50), Egger’s test of intercept
(P = .26), and Duval and Tweedie’s trim and ﬁll test (no
studies added) all indicated that there was no clear evidence
of publication bias. Pooled 5-year OS estimates of abstracts
andfulltextreportswerenotsigniﬁcantlydiﬀerent(P = .87).
Tests forpublication bias repeated afterinclusion of abstracts
showed that adding abstracts did not add any signiﬁcant
value.
4. Discussion
Despite the established worse outcome of anthracycline-
based chemotherapy in PTCL patients compared to aggres-
sive B-cell NHL [2–4], such regimens, especially CHOP,
have remained the standard treatment for PTCL. In this
meta-analysis,theCRrateachievedwithanthracycline-based
regimens ranged from 36% in ETTL to 66% in ALCL. Five-
year OS across PTCL subtypes also ranged widely from 20%
in ETTL to 57% in ALCL. As has already been established
[4, 40], ALCL patients had a markedly better 5-year OS
than other PTCL patients (57% versus 37%, P<. 001).
However, it is worth noting here that the majority of studies
didnotreportontheALKstatusofALCLpatients.Resultson
ALK-negativeandALK-positiveALCLpatientsweregrouped
together in most studies. Only three studies that reported
on ALK-negative ALCL had suﬃcient data to be included
in the meta-analysis [1, 15, 17]a n dr e v e a l e daC Rr a t eo f
62% and a 5-year OS of 49% [1] in this subgroup. Although
ALK-negative ALCL has poorer outcomes when compared
to ALK-positive ALCL, both subsets of ALCL appear to have
superior outcomes when compared to other PTCL subtypes.ISRN Hematology 7
Table 3: Metaregression of predictors of complete response rate.
Predictor variable CR
Coeﬃcient P value
%a g e> 60 −0.029 .03
Gender, male 0.026 .27
% stage III/IV −0.015 .046
%Bs y m p t o m s −0.036 .012
% extra-nodal disease 0.011 .25
% high LDH > ULN −0.037 .26
%E C O G≥ 2 −0.008 .46
% bone Marrow Positive −0.026 .28
% high/high Inter IPI −0.016 .056
Note: only prospective studies were included in the metaregression.
4.1. Study Limitations. Until recently, the majority of our
knowledge about treatment outcomes in PTCL emerged
from small phase 2 studies. Hence, the data included in this
meta-analysis comes from phase 2 clinical trials with all the
inherent drawbacks of such studies. Additionally, the low
prevalence of PTCL and its heterogeneity makes it diﬃcult
to draw conclusions from most of these small individual
studies. It should also be noted that there were no consistent
standards for reporting results. This limited the number of
studies eligible for inclusion. Moreover, most studies did
not specify the timing and criteria for CR determination
and utilized investigator determination of CR rather than
centralreview.ThismightleadtooverestimateoftheCRrate.
Some studies did not report CR and OS for PTCL subtypes
separately. These contributed to the review of overall CR and
5-year OS rates but not to subtype estimates.
High-quality meta-analyses often utilize data from ran-
domized, double-blinded, controlled trials with descriptions
of dropouts and withdrawals [55]. We did not perform
Jadad scoring of individual trials because PTCL and its
subtypes are rare diseases that precluded performance of
large randomized trials. While, in an ideal setting, a meta-
analysisforPTCLswouldutilizedatafromrandomizedphase
3 trials, our meta-analyses represent a review of the best
available data from existing publications on the treatment of
PTCL.
Another concern raised by previous studies is the het-
erogeneity of PTCL populations in the published literature.
This was addressed by separating out PTCL subtypes before
computing estimates of CR and 5-year OS rates. Moreover,
there was heterogeneity in reporting of data across studies.
The meta-analysis of CR rate for PTCL, NOS, and PTCL as
a whole group was associated with moderate heterogeneity
(I2 71% and 59%, resp.) as was the meta-analysis of 5-year
OS rate for PTCL and NOS (I2 = 54%), while for NK/T-cell,
n a s a ll y m p h o m a ,a n dP T C La saw h o l eg r o u pw a sa s s o c i a t e d
with high degree of heterogeneity (I2 > 75%). To address
this, random eﬀects models were used but this degree of
inconsistency may yield instability in the results. Neverthe-
less, these analyses represent the best available data for these
rare disease entities and may only be improved by larger
randomizedcontrolledtrialswhichhavenotbeenperformed
to date and may not be practical for some PTCL subsets.
We attempted to estimate the PFS rates achieved with
anthracycline-based regimens, but while some authors
reported PFS rates, others presented DFS or EFS rates
without consistent deﬁnitions of events precluding combi-
nation. Unfortunately, the international prognostic index
was not reported for the majority of patients participating
in the included trials. However, whenever available, we
extracted patient data and included it in the metaregression
ofpredictorsofCRshowninTable 3.Moreover,somestudies
included in the meta-analysis of CR rates were presentations
of early results and had insuﬃcient followup to be included
in the meta-analysis of 5-year OS.
As in any meta-analysis, there was concern for publi-
cation bias. We addressed this issue using funnel plots and
statistical testing and did not ﬁnd evidence suggestive of
overt publication bias. We also compared analysis with the
addition of meeting abstracts that were not published as full
manuscripts and determined that adding these studies did
not inﬂuence our results.
Since retrospective studies are subject to selection, recall,
and other biases, we also analyzed prospective studies
separately. When only prospective studies included in the
meta-analysis of CR were examined, PTCL as a whole group
demonstrated substantial heterogeneity (I2 = 69%), AITL,
ALK-negative ALCL, and NK/T demonstrated no evidence
of heterogeneity (all I2 = 0%), and ETTL demonstrated
moderate heterogeneity (I2 = 50%). The estimated CR rate
for PTCL subtypes when analyses are limited to prospective
studies were as follows: NK/T 72.7% (95% CI 53.3–86.1%),
ALK-negative ALCL 61.6% (95% CI 23.6–89.3%), ETTL
43.3% (95% CI 20.1–69.8%), and AITL 34.3% (95% CI
23.3–47.4%), which diﬀer somewhat from the response rates
reportedabove.Sincetherewereonlytwoprospectivestudies
reporting 5-year OS, separate analysis was not performed.
4.2. Summary of Findings
4.2.1. Is There a Beneﬁt for Anthracyclines in the Treatment
of PTCL Patients outside of the ALCL Subsets? To answer
this question it may be useful to look at the results of
anthracycline-based regimens in the treatment of other NHL
subtypes where their beneﬁt has already been established.
While the CR rate of 52% from this meta-analysis achieved
with anthracyclines in the treatment of PTCL patients
(excluding ALK-positive ALCL) seems comparable to the
44%–63% CR rates obtained with CHOP chemotherapy
in diﬀuse large B-cell lymphoma (DLBCL) patients in the
pre-rituximab era [48, 56], the estimated 5-year OS for
PTCL patients was only 35% compared to the 41% in
intermediate-grade NHL in general [57] and 45%–70% in
DLBCL [58–60]. Moreover, the International PTCL Clinical
and Pathologic Review Project retrospectively demonstrated
no diﬀerence in OS comparing patients who did and did not
receive an anthracycline for any subtype of PTCL [1].
4.2.2. What Modiﬁcations to the Current Anthracycline-
Based Regimens Could Improve Treatment Outcomes in PTCL
Patients? Modiﬁcations in dose density and intensity of8 ISRN Hematology
AITL Siegert et al., 1992 [12]  0.330 0.202 0.490
López-Guillermo et al., 1998 [23]  0.370 0.198 0.583
Pautier et al., 1999 [24]  0.606 0.433 0.756
Kim et al., 2002 [27] 0.400 0.100 0.800
Reiser et al., 2002 [28]  0.286 0.072 0.674
Reimer et al., 2004 [15] 0.333 0.131 0.624
Savage et al., 2004 [32] 0.700 0.376 0.900
Sonnen et al. , 2005 [36]  0.360 0.218 0.531
Kim et al., 2006 [17] 0.500 0.059 0.941
Sung et al., 2006 [19] 0.400 0.100 0.800
Fixed 0.421 0.346 0.499
Random 0.421 0.339 0.509
ALCL López-Guillermo et al., 1998 [23]  0.690 0.507 0.828
Kim et al., 2002 [27]  0.692 0.409 0.879
Reiser et al., 2002 [28]   0.790 0.555 0.919
Savage et al., 2004 [32]  0.550 0.381 0.708
Sonnen et al., 2005 [36]  0.710 0.488 0.863
Sung et al., 2006 [19]  0.100 0.006 0.674
Fixed 0.654 0.561 0.736
Random 0.658 0.540 0.759
Alk Neg ALCL Reimer et al., 2004 [15]  0.500 0.123 0.877
Kim et al., 2006 [48]  0.833 0.194 0.990
Fixed 0.616 0.236 0.893
Random 0.616 0.236 0.893
ETTL López-Guillermo et al., 1998 [23]  0.270 0.094 0.569
Daum et al., 2003 [14]  0.350 0.186 0.559
Savage et al., 2004 [32]  0.330 0.109 0.664
Wöhrer et al., 2004 [16]  0.300 0.100 0.624
Bishton and Haynes, 2007 [20]  0.833 0.369 0.977
Fixed 0.356 0.241 0.490
Random 0.359 0.234 0.507
NK/T nasal Kwong et al., 1997 [22]  0.667 0.461 0.824
Cheung et al., 1998 [2]  0.560 0.423 0.689
López-Guillermo et al., 1998 [23]  0.460 0.229 0.709
Ribrag et al., 2001 [25]  0.286 0.072 0.674
Cheung et al., 2002 [26]  0.656 0.529 0.764
Kim et al., 2002 [27]  0.520 0.331 0.704
Chim et al., 2004 [30]  0.660 0.514 0.780
Li et al., 2004 [31]  local 0.500 0.284 0.716
Li et al., 2004 [31]  syst 0.600 0.297 0.842
Reimer et al., 2004 [15]  0.833 0.194 0.990
Savage et al., 2004 [32]  0.730 0.481 0.887
You et al., 2004 [33]   0.031 0.002 0.350
Kim et al., 2005 [35]  0.375 0.179 0.623
Kim et al., 2006 [17]  0.625 0.285 0.875
Lee et al., 2006 [18]  0.765 0.515 0.909
Li et al., 2006 [37]   0.333 0.043 0.846
Fixed 0.589 0.533 0.643
Random 0.578 0.504 0.649
Non-ALCL PTCL Rudiger et al., 2002 [29]  0.005 0.000 0.077
Escalón et al., 2005 [34]  CHOP 0.580 0.380 0.756
Escalón et al., 2005 [34]  intensive CHOP 0.590 0.453 0.714
Takamatsu et al., 2010 [21]  0.410 0.209 0.646
PTCL-NOS Cheung et al., 1998 [2]   0.696 0.490 0.845
López-Guillermo et al., 1998 [23]   0.470 0.372 0.570
Kim et al., 2002 [27]   0.516 0.345 0.683
Reiser et al., 2004 [28]  0.607 0.420 0.767
Reimer et al., 2004 [15]  0.417 0.185 0.692
Savage et al., 2004 [32]  0.641 0.550 0.723
Sonnen et al., 2005 [36]  0.550 0.433 0.662
Kim et al., 2006 [17]  0.571 0.316 0.793
Sung et al., 2006 [19]  0.171 0.084 0.317
PTCL combined Coiffer et al., 1990 [3]  0.720 0.628 0.796
Liang et al., 1992 [11]  0.670 0.516 0.794
Karakas et al., 1996 [13]  0.770 0.577 0.891
Gisselbrecht et al., 1998 [4]  0.540 0.482 0.597




Alk Neg ALCL summary estimate
ETTL summary estimate
NK/T nasal summary estimate
 
Figure 2: Meta-analysis of complete response rate of patients undergoing anthracycline-based chemotherapy by PTCL subtype. Forest plot
of the complete response rate along with summary estimates and its 95% CI in diamonds. Horizontal lines show the 95% CI for each
trial. Only subtypes showing no evidence of heterogeneity were grouped. Within each subtypes, studies were ordered by year of reporting
and alphabetical order. Squares on the plot are proportional to the weight of each study. Fixed eﬀect and random eﬀects models summary
estimates are depicted in boldface.ISRN Hematology 9
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Figure 3: Funnel plot of standard error by logit complete response
rate. The funnel plot of studies included in the meta-analysis of
complete response rate illustrates the standard error and logit of
complete response rate.
CHOP-type regimens (like DI-CHOP) may overcome the
high rate of disease progression and induce better long-term
responses in PTCL [18, 47]. The German high-grade NHL
study group has previously shown that reducing the interval
between CHOP cycles from 21 days to 14 days improves
EFS [45]a sw e l la sO S[ 45, 46]. Another recent approach
to improve eﬃcacy of CHOP regimen was substituting
doxorubicin with pegylated liposomal doxorubicin, which
was suggested to persist in the blood circulation signiﬁcantly
longer than doxorubicin [61].
Addition of Other Active Agents? Other modiﬁcations to
the CHOP-based chemotherapy include the addition of
etoposide [45, 46], bortezomib, and purine analogs [17, 62–
68]. Although the addition of etoposide to CHOP-based
regimens improved CR in T-NHL patients in some studies,
EFS and OS rates have been disappointing when compared
to B-NHL [13, 69, 70]. On the other hand, encouraging
results have been achieved adding gemcitabine to CHOP-
etoposideinthefront-linesetting[17,68].Anotherapproach
to overcome drug resistance in PTCL is the combination
of CHOP with the proteasome inhibitor bortezomib. This
currentlyisbeinginvestigatedinaphase1/2studyinpatients
with advanced stage PTCL [71].
Another option for improving the outcome of
anthracycline-based chemotherapy in PTCL is combining
the anti-angiogenic agent bevacizumab with CHOP (A-
CHOP). The basis of this combination emerges from the
ﬁndingthatserumconcentrationsofthevascularendothelial
growth factor (VEGF) have an independent prognostic
inﬂuence on survival in NHL [72]. Moreover, signiﬁcant
expression of VEGF transcripts was observed in PTCL,
particularlyinAITL[73].Thiscombinationhasbeenstudied
in the Eastern Cooperative Oncology Group (ECOG).
Incorporation of Immunotherapy? The signiﬁcant improve-
ments in response rates and survival achieved by adding
rituximab to CHOP-type chemotherapy in DLBCL [56,
60, 74] triggered the investigation of similar chemo-
immunotherapy combinations in PTCL. The interim anal-
ysis of the CONCEPT phase 2 study of denileukin difti-
tox in combination with CHOP revealed a 68% overall
response rate and 57%CR in patients with PTCL [75]. Long-
term results are still awaited. Alemtuzumab-chemotherapy
combinations also have been evaluated in several studies
[76–78]. Alemtuzumab-CHOP combinations in the front-
line treatment of non-ALCL PTCL patients resulted in 60–
80%CR rate with estimated 2-year OS of 53–75% [79]. The
estimated 2-year EFS in those studies ranged between 40%
and 50%. Moreover, the combination of alemtuzumab with
ﬂudarabine-cyclophosphamide-doxorubicin induced remis-
sion in 63% (58%CR) of ALK-negative PTCL patients
treated in the front-line setting [80]. However, infections
have been a concern in all alemtuzumab-combination stud-
ies.
Incorporation of Radiation Therapy? The addition of RT
also may be important particularly in NK/T cell lym-
phoma. Our meta-analysis revealed that anthracycline-based
chemotherapy alone resulted in a CR rate of 49% (95%
CI 38.7–59.5%) while chemoradiotherapy resulted in CR
of 59.6% (95% CI 42–75%; P = .02). However, these
results cannot be used as strong evidence to the beneﬁts of
combination of chemoradiotherapy in NK/T-cell lymphoma
over chemotherapy alone, since most studies included in this
meta-analysis did not report treatment results in relation to
the extent and stage of the disease [18, 26, 30, 31, 33, 35,
37, 43, 47, 81]. Clarifying the beneﬁts of chemoradiotherapy
over chemotherapy in NK/T cell NHL will require larger
randomized controlled clinical trials.
Consolidating Responses with Hematopoietic Stem Cell Trans-
plant? Since the major diﬃculty in the treatment of PTCL
with conventional chemotherapy has been sustaining CR
[3, 23, 27, 29, 39], autologous and allogeneic hematopoietic
stem cell transplant have been explored as ways to consoli-
date remissions and prolong survival among PTCL patients
treated with anthracycline-based regimens. However, there
has been conﬂicting data regarding the advantage of per-
forming transplantation in ﬁrst remission in PTCL [82–90].
4.2.3. What Are the Alternatives to Anthracyclines in PTCL
Management? In the search for nonanthracycline alterna-
tives, some agents have demonstrated promise as single
agents in NHL in general and PTCL in particular. Of those
are the anti-folate agents, such as pralatrexate, which showed
28%overallresponserateinpatientswithrelapsed/refractory
PTCL and 49% rate of disease control leading to its FDA
approval in this setting [91]. Moreover, the activity of purine
nucleoside analogues such as pentostatin, nelarabine, and
gemcitabine appears promising as well [62–67, 92]. Histone
deacetylase (HDAC) inhibitors, such as vorinostat and
romidepsin, are another promising group of agents that are
being tested as single agents or in combination in treatment
of PTCL both front-line and relapsed/refractory settings [93,
94]. Although nonanthracycline-based chemotherapy seems10 ISRN Hematology
PTCL subgroup Study, year 5-year OS rate and 95% CI 5-year OS rate  95% CI 
AITL Pautier et al., 1999 [24]  0.360 0.217 0.534
Savage et al., 2004 [32]  0.360 0.134 0.672
Sonnen et al., 2005 [36]  0.280 0.155 0.451
Vose et al., 2008 [1]  0.320 0.264 0.381
Fixed AITL summary estimate 0.321 0.272 0.375
Random 0.321 0.272 0.375
ALCL Gisselbrecht et al., 1998 [4]  0.640 0.512 0.751
Savage et al., 2004 [32]  0.430 0.275 0.600
Sonnen et al., 2005 [36]  0.610 0.394 0.790
Fixed ALCL summary estimate 0.573 0.479 0.662
Random 0.565 0.428 0.692
Alk Neg ALCL Vose et al., 2008 [1]  0.490 0.377 0.604
Fixed Alk Neg ALCL summary estimate 0.490 0.377 0.604
Random 0.490 0.377 0.604
ETTL Savage et al., 2004 [32]  0.220 0.055 0.577
Vose et al., 2008 [1]  0.200 0.118 0.318
Fixed ETTL summary estimate 0.203 0.125 0.312
Random 0.203 0.125 0.312
NK/T nasal Cheung et al., 2002 [26]  0.403 0.288 0.530
Li et al., 2004 [31]  local 0.150 0.046 0.392
Li et al., 2004 [31]  syst 0.300 0.100 0.624
Savage et al., 2004 [32]  0.240 0.094 0.490
You et al., 2004 [33]  0.200 0.066 0.470
Kim et al., 2005 [35]  0.590 0.347 0.796
Li et al., 2006 [37]  0.760 0.647 0.845
Vose et al., 2008 [1]  0.420 0.340 0.504
Non-ALCL PTCL Gisselbrecht et al., 1998 [4]  0.350 0.291 0.414
Rudiger et al., 2002 [29]  0.260 0.182 0.357
PTCL combined Karakas et al., 1996 [13]  0.480 0.303 0.663
Kim et al., 2002 [27]  0.526 0.415 0.633
Reiser et al., 2002 [28]  0.550 0.429 0.665
PTCL-NOS Savage et al., 2004 [32]  0.350 0.269 0.440
Sonnen et al., 2005 [36]  0.450 0.338 0.567
Vose et al., 2008 [1]  0.320 0.273 0.371
0% 50% 100%
Figure 4: Meta-analysis of 5-year overall survival rate of patients undergoing anthracycline-based chemotherapy by PTCL subtype. Forest
plot of the complete response rate along with summary estimates and its 95% CI in diamonds. Horizontal lines show the 95% CI for each
trial. Only subtypes showing no evidence of heterogeneity were grouped. Within each subtypes, studies were ordered by year of reporting
and alphabetical order. Squares on the plot are proportional to the weight of each study. Fixed eﬀect and random eﬀects models summary
estimates are depicted in boldface.
an attractive alternative, comparative studies are needed to
establish its beneﬁt over anthracyclines in PTCL.
5. Conclusion
Despite achieving CR with front-line anthracycline-based
therapy in more than half of PTCL patients, 5-year OS
remains poor for most PTCL subtypes. Although CHOP
remains the standard front-line therapy for PTCL, given
these poor outcomes, most PTCL patients (with the excep-
tion of ALK-positive ALCL) should be considered for clinical
trials of initial therapy. Future clinical trials need to focus on
subtype-speciﬁc treatment, incorporation of newer agents,
and nonanthracycline-based combinations to improve the
long-term outcome for PTCL patients. Moreover, strategies
capable of sustaining responses such as maintenance therapy
and transplant consolidation should be actively investigated
in prospective clinical trials. Given the small number of
PTCL patients seen by any single institution, such trials
need to be multicentered and community oncologists should
encourage their patients to enroll in such studies whenever
available.ISRN Hematology 11




















Logit 5-year OS rate
Figure 5: Funnel plot of standard error by logit 5-year overall
survival rate. The funnel plot of studies included in the meta-
analysis of 5-year overall survival rate illustrates the standard error
and logit of 5-year overall survival rate.
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